Ocugen pays $15 mn upfront to Bharat Biotech for Covaxin rights in Canada
The Hindu
Similar to the US arrangement, Ocugen will retain 45 per cent of the profit from sales of Covaxin in Canada.
Ocugen Inc, the US partner for has announced the payment of $15 million upfront to the Indian drug maker for extending the vaccine rights to Canada. Ocugen in a regulatory filing said it has agreed to pay another $10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country. Also read:More Related News
According to BACL, the biophilic-inspired business park will offer smart workspaces within a vibrant public realm. The project’s most exceptional and breathtaking attribute lies in the Urban Forest, a lush oasis in the centre of the development. This green space will serve as a focal point, seamlessly blending indoor and outdoor spaces throughout the area. The upcoming metro station in Airport City will provide seamless connectivity to the business park from the northern side, ensuring convenient accessibility.